- Home
- INTS vs NXTC Comparison
INTS vs NXTC Comparison
Compare INTS & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- NXTC
- Stock Information
- Founded
- INTS 2012
- NXTC 2015
- Country
- INTS United States
- NXTC United States
- Employees
- INTS N/A
- NXTC N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- INTS Health Care
- NXTC Health Care
- Exchange
- INTS Nasdaq
- NXTC Nasdaq
- Market Cap
- INTS 12.2M
- NXTC 13.0M
- IPO Year
- INTS 2023
- NXTC 2019
- Fundamental
- Price
- INTS $0.31
- NXTC $6.41
- Analyst Decision
- INTS Strong Buy
- NXTC Strong Buy
- Analyst Count
- INTS 4
- NXTC 2
- Target Price
- INTS $4.50
- NXTC $25.50
- AVG Volume (30 Days)
- INTS 5.0M
- NXTC 12.5K
- Earning Date
- INTS 11-12-2025
- NXTC 11-06-2025
- Dividend Yield
- INTS N/A
- NXTC N/A
- EPS Growth
- INTS N/A
- NXTC N/A
- EPS
- INTS N/A
- NXTC N/A
- Revenue
- INTS N/A
- NXTC N/A
- Revenue This Year
- INTS N/A
- NXTC N/A
- Revenue Next Year
- INTS N/A
- NXTC N/A
- P/E Ratio
- INTS N/A
- NXTC N/A
- Revenue Growth
- INTS N/A
- NXTC N/A
- 52 Week Low
- INTS $0.19
- NXTC $2.69
- 52 Week High
- INTS $3.75
- NXTC $19.20
- Technical
- Relative Strength Index (RSI)
- INTS 64.31
- NXTC 67.64
- Support Level
- INTS $0.27
- NXTC $5.69
- Resistance Level
- INTS $0.30
- NXTC $6.99
- Average True Range (ATR)
- INTS 0.03
- NXTC 0.36
- MACD
- INTS 0.01
- NXTC 0.07
- Stochastic Oscillator
- INTS 60.25
- NXTC 70.40
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.